Clinical trial results for SIIPL Tdap are online

The Phase II/III study, conducted in Germany, assessed the safety and immunogenicity of SIIPL Tdap, a novel booster vaccine for tetanus, diphtheria, and pertussis.

This publication represents a significant step forward in vaccine development and underscores our commitment to advancing healthcare solutions. We invite you to read the full clinical trial publication for detailed insights into this exciting research.

For more details, you can read the full publication here.